<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802203</url>
  </required_header>
  <id_info>
    <org_study_id>CSA-003</org_study_id>
    <nct_id>NCT01802203</nct_id>
  </id_info>
  <brief_title>trūFreeze® Spray Cryotherapy Patient Registry</brief_title>
  <official_title>trūFreeze® Spray Cryotherapy Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSA Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for
      the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center registry of patients who are currently undergoing spray
      cryotherapy using the trūFreeze® device. The registry population consists of patients who are
      being treated using the spray cryotherapy trūFreeze® device for the removal of unwanted
      tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal
      settings.

      Patients eligible to participate in the registry will have disease and treatment specific
      data collected throughout therapy and long-term follow-up. Subjects will be considered to
      have completed the registry when data from the 5 year follow-up visit has been collected. The
      beginning of the follow-up period commences with the first endoscopic treatment session.

      Subjects may be withdrawn prior to this for any of the following reasons:

        1. Death, or

        2. Lost to Follow-Up, or

        3. Withdrawal of consent, or

        4. Discontinuation by the investigator. Three attempts at contact using two different
           methods are required prior to determination that the subject is lost to follow-up.
           Attempts at contact must be with certified letters OR documented telephone contact.

      The registry will utilize electronic case report forms using a web-based platform housed at
      the University of North Carolina at Chapel Hill. Access to the database will be limited to
      individuals involved in the research registry and will require a unique user ID and password.
      All access to the database and web-based application will be encrypted (HTTPS) and electronic
      systems compliant with applicable privacy and security regulations. To maintain patient
      confidentiality, all subjects will be assigned a registry identification number, and this
      will be the only link between subject identity and treatment information. Read-only access
      will be provided to any personnel who is not an administrator or responsible for data entry.

      All data requested on the case report form must be recorded. All missing data must be
      explained. The system allows sites to directly enter data electronically, however sites are
      still responsible for ensuring they have source documents that support all data entered
      electronically that are separate and verifiable. The registry system will maintain an audit
      trail that captures when electronic entries are changed, what the change was, and who made
      the change.

      The investigators will ensure the capability for inspections of applicable registry-related
      facilities (e.g. pharmacy, diagnostic laboratory, etc.). The registry will be monitored by
      the sponsor, and allow auditing by the Institutional Review Board, government regulatory
      bodies, and University compliance and quality assurance groups of all registry related
      documents (e.g. source documents, regulatory documents, data collection instruments, registry
      data, etc.).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.</measure>
    <time_frame>5 years</time_frame>
    <description>The registry population consists of patients who are being treated using the trūFreeze® spray cryotherapy device for the removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary or gastrointestinal settings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.</measure>
    <time_frame>5 years</time_frame>
    <description>All adverse events occurring during the registry period must be recorded. The clinical course of each event should be followed until resolution, stabilization, or until it has been determined that the registry treatment or participation is not the cause. Serious adverse events that are still ongoing at the end of the Spray Cryotherapy Patient Registry registry period must be followed up to determine the final outcome. Any serious adverse event that occurs after the registry period and is considered to be possibly related to the trūFreeze® spray cryotherapy device or registry participation should be recorded and reported immediately.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">275</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Dysplasia</condition>
  <condition>Esophageal Neoplasm</condition>
  <condition>Esophageal Stenosis</condition>
  <condition>Bronchial Neoplasm</condition>
  <condition>Stenosis of Bronchus or Trachea</condition>
  <arm_group>
    <arm_group_label>truFreeze spray cryotherapy</arm_group_label>
    <description>truFreeze Spray Cryotherapy administered as routine clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>truFreeze Spray Cryotherapy</intervention_name>
    <description>spray cryotherapy</description>
    <arm_group_label>truFreeze spray cryotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are being treated using the trūFreeze® spray cryotherapy device for the
        removal of unwanted tissue, such as malignant or pre-malignant conditions in the pulmonary
        or gastrointestinal (GI) setting.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. GI conditions include:

               -  Barrett's Esophagus (BE) with or without dysplasia

               -  Squamous dysplasia

               -  Esophageal cancer, any stage

          2. Pulmonary conditions include:

               -  Any endobronchial cancerous or precancerous disease located within the central
                  airways

               -  Any non-malignant endobronchial process of the central airways that results in
                  abnormal mucosa (i.e. granulation tissue, papillomatosis, sarcoidosis,
                  tuberculosis, etc.)

               -  Tracheal or bronchial stenosis (malignant or benign)

               -  Any pleural disease, malignant or benign All subjects are required to be able to
                  provide written informed consent

        Exclusion Criteria:

          1. Gastrointestinal Exclusion Criteria

               -  Contraindication to spray cryotherapy.

               -  Prior treatment with spray cryotherapy. Previous or concurrent treatment using
                  other mucosal therapies such as endoscopic mucosal resection or radiofrequency
                  ablation is acceptable.

               -  Below 18 years of age

          2. Pulmonary Exclusion Criteria

               -  Contraindication to spray cryotherapy.

               -  Prior treatment with spray cryotherapy. Previous or concurrent treatment using
                  other mucosal therapies is acceptable.

               -  Tracheoesophageal fistula.

               -  Bronchopleural fistula.

               -  Current untreated pneumothorax.

               -  Clinically significant hypoxia refractory to supplemental oxygen therapy.

               -  Below 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Shaheen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert F Browning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Military Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Green Hosptial</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <zip>70065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHEALTH Care Associates</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester/Strong Memorial Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahuja Medical Center-CWR University Hosptials</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.</citation>
    <PMID>22237781</PMID>
  </reference>
  <reference>
    <citation>Heier SK. Evaluation of candidate therapies for ablation of Barrett's in a canine model. Gastrointestinal endoscopy. 1996;43(4):337</citation>
  </reference>
  <reference>
    <citation>Pasricha PJ, Hill S, Wadwa KS, Gislason GT, Okolo PI 3rd, Magee CA, Canto MI, Kuo WH, Baust JG, Kalloo AN. Endoscopic cryotherapy: experimental results and first clinical use. Gastrointest Endosc. 1999 May;49(5):627-31. Review.</citation>
    <PMID>10228263</PMID>
  </reference>
  <reference>
    <citation>Greenwald BD, Dumot JA, Horwhat JD, Lightdale CJ, Abrams JA. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2010 Jan;23(1):13-9. doi: 10.1111/j.1442-2050.2009.00991.x. Epub 2009 Jun 9.</citation>
    <PMID>19515183</PMID>
  </reference>
  <reference>
    <citation>Graña L, Ablin RJ, Goldman S, Milhouse E Jr. Freezing of the esophagus: histological changes and immunological response. Int Surg. 1981 Oct-Dec;66(4):295-301.</citation>
    <PMID>7345039</PMID>
  </reference>
  <reference>
    <citation>Loprinzi CL, Foote RL, Michalak J. Alleviation of cytotoxic therapy-induced normal tissue damage. Semin Oncol. 1995 Apr;22(2 Suppl 3):95-7. Review.</citation>
    <PMID>7740323</PMID>
  </reference>
  <reference>
    <citation>Rodgers BM, Pappelis P. Profound endoesophageal cryotherapy. Cryobiology. 1985 Feb;22(1):86-92.</citation>
    <PMID>3979079</PMID>
  </reference>
  <reference>
    <citation>Laugier P, Berger G. Assessment of echography as a monitoring technique for cryosurgery. Ultrason Imaging. 1993 Jan;15(1):14-24.</citation>
    <PMID>8328116</PMID>
  </reference>
  <reference>
    <citation>Reiser M, Drukier AK, Ultsch B, Feuerbach S. The use of CT in monitoring cryosurgery. Eur J Radiol. 1983 May;3(2):123-8.</citation>
    <PMID>6873073</PMID>
  </reference>
  <reference>
    <citation>Myers B, Donovan W. Cryosurgery of the anus. South Med J. 1977 Jan;70(1):17-8.</citation>
    <PMID>841369</PMID>
  </reference>
  <reference>
    <citation>McKelvie P. Cryotherapy in the upper air and food passages. Proc R Soc Med. 1975 Oct;68(10):610.</citation>
    <PMID>54925</PMID>
  </reference>
  <reference>
    <citation>Kuflik EG. Cryosurgery updated. J Am Acad Dermatol. 1994 Dec;31(6):925-44; quiz 944-6. Review.</citation>
    <PMID>7962774</PMID>
  </reference>
  <reference>
    <citation>Rodgers BM, McDonald AP, Talbert JL, Donnelly WH. Morphologic and functional effects of esophageal cryotherapy. J Thorac Cardiovasc Surg. 1979 Apr;77(4):543-9.</citation>
    <PMID>423587</PMID>
  </reference>
  <reference>
    <citation>Kantsevoy SV, Cruz-Correa MR, Vaughn CA, Jagannath SB, Pasricha PJ, Kalloo AN. Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc. 2003 Mar;57(3):403-6.</citation>
    <PMID>12612530</PMID>
  </reference>
  <reference>
    <citation>Greenwald BD, Dumot JA, Abrams JA, Lightdale CJ, David DS, Nishioka NS, Yachimski P, Johnston MH, Shaheen NJ, Zfass AM, Smith JO, Gill KR, Burdick JS, Mallat D, Wolfsen HC. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 2010 Apr;71(4):686-93. doi: 10.1016/j.gie.2010.01.042.</citation>
    <PMID>20363410</PMID>
  </reference>
  <reference>
    <citation>Dumot JA, Vargo JJ 2nd, Falk GW, Frey L, Lopez R, Rice TW. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009 Oct;70(4):635-44. doi: 10.1016/j.gie.2009.02.006. Epub 2009 Jun 25.</citation>
    <PMID>19559428</PMID>
  </reference>
  <reference>
    <citation>Finley DJ, Dycoco J, Sarkar S, Krimsky WS, Sherwood JT, Dekeratry D, Downie G, Atwood J, Fernando HC, Rusch VW. Airway spray cryotherapy: initial outcomes from a multiinstitutional registry. Ann Thorac Surg. 2012 Jul;94(1):199-203; discussion 203-4. doi: 10.1016/j.athoracsur.2012.01.112. Epub 2012 Apr 18.</citation>
    <PMID>22516831</PMID>
  </reference>
  <reference>
    <citation>Au JT, Carson J, Monette S, Finley DJ. Spray cryotherapy is effective for bronchoscopic, endoscopic and open ablation of thoracic tissues. Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):580-4. Epub 2012 Jul 18.</citation>
    <PMID>22811511</PMID>
  </reference>
  <reference>
    <citation>Krimsky WS, Rodrigues MP, Malayaman N, Sarkar S. Spray cryotherapy for the treatment of glottic and subglottic stenosis. Laryngoscope. 2010 Mar;120(3):473-7. doi: 10.1002/lary.20794.</citation>
    <PMID>20058314</PMID>
  </reference>
  <reference>
    <citation>Fernando HC, Dekeratry D, Downie G, Finley D, Sullivan V, Sarkar S, Rivas R Jr, Santos RS. Feasibility of spray cryotherapy and balloon dilation for non-malignant strictures of the airway. Eur J Cardiothorac Surg. 2011 Nov;40(5):1177-80. doi: 10.1016/j.ejcts.2011.02.062. Epub 2011 Apr 8.</citation>
    <PMID>21482131</PMID>
  </reference>
  <reference>
    <citation>Evantash E, Hill EC, Pernoll ML. Benign disorders of the uterine cervix. Current Obstetric&amp; Gynecologic, Diagnosis &amp; Treatment. 9th ed. Beijing: The McGraw-Hill Companies. 2003:677-692</citation>
  </reference>
  <reference>
    <citation>Holschneider CH. Premalignant and malignant disorders of the uterine cervix. Current Diagnosis and Treatment Obstetrics and Gynecology,. 2007:833-854</citation>
  </reference>
  <reference>
    <citation>Jacob M, Broekhuizen FF, Castro W, Sellors J. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet. 2005 May;89 Suppl 2:S13-20. Review.</citation>
    <PMID>15823262</PMID>
  </reference>
  <reference>
    <citation>Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinomas. Am Fam Physician. 2004 Oct 15;70(8):1481-8.</citation>
    <PMID>15526735</PMID>
  </reference>
  <reference>
    <citation>Jaros E, Príborský J. [15 years' clinical experience in cryodestruction of malignant disorders in the anorectum]. Rozhl Chir. 1999 Sep;78(9):473-7. Czech.</citation>
    <PMID>11077879</PMID>
  </reference>
  <reference>
    <citation>Cestari A, Guazzoni G, dell'Acqua V, Nava L, Cardone G, Balconi G, Naspro R, Montorsi F, Rigatti P. Laparoscopic cryoablation of solid renal masses: intermediate term followup. J Urol. 2004 Oct;172(4 Pt 1):1267-70.</citation>
    <PMID>15371821</PMID>
  </reference>
  <reference>
    <citation>Powell T, Whelan C, Schwartz BF. Laparoscopic renal cryotherapy: biology, techniques and outcomes. Minerva Urol Nefrol. 2005 Jun;57(2):109-18. Review.</citation>
    <PMID>15951735</PMID>
  </reference>
  <reference>
    <citation>Goldberg SR, Neifeld JP. Incidentally discovered gallbladder cancer: role of cryotherapy. J Surg Oncol. 2004 Aug 1;87(2):91-4.</citation>
    <PMID>15282703</PMID>
  </reference>
  <reference>
    <citation>Dong K, Li B, Guan QL, Huang T. Analysis of multiple factors of postsurgical gastroparesis syndrome after pancreaticoduodenectomy and cryotherapy for pancreatic cancer. World J Gastroenterol. 2004 Aug 15;10(16):2434-8.</citation>
    <PMID>15285038</PMID>
  </reference>
  <reference>
    <citation>Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005 Dec;62(6):842-8.</citation>
    <PMID>16301023</PMID>
  </reference>
  <reference>
    <citation>Johnston MH. Cryoablation of Dysplasia in Barrett's Esophagus (BE) and Early Stage Esophageal Cancer. Gastrointestinal endoscopy. 2006;63(5):AB223</citation>
  </reference>
  <reference>
    <citation>Johnston MH. Reversal of barrett's esophagus with cryotherapy. The American journal of gastroenterology. 2003;98:S11</citation>
  </reference>
  <reference>
    <citation>Johnston MH. Cryotherapy and other newer techniques. Gastrointest Endosc Clin N Am. 2003 Jul;13(3):491-504. Review.</citation>
    <PMID>14629105</PMID>
  </reference>
  <reference>
    <citation>Shaheen NJ, Greenwald BD, Peery AF, Dumot JA, Nishioka NS, Wolfsen HC, Burdick JS, Abrams JA, Wang KK, Mallat D, Johnston MH, Zfass AM, Smith JO, Barthel JS, Lightdale CJ. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc. 2010 Apr;71(4):680-5. doi: 10.1016/j.gie.2010.01.018.</citation>
    <PMID>20363409</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett esophagus</keyword>
  <keyword>Esophageal dysplasia</keyword>
  <keyword>Upper gastrointestinal squamous dysplasia</keyword>
  <keyword>Esophageal cancer</keyword>
  <keyword>Endobronchial cancer</keyword>
  <keyword>Central airway cancer</keyword>
  <keyword>Central airway precancerous disease</keyword>
  <keyword>Central airway granulation tissue</keyword>
  <keyword>Central airway papillomatosis</keyword>
  <keyword>Central airway sarcoidosis</keyword>
  <keyword>Central airway tuberculosis</keyword>
  <keyword>Tracheal stenosis</keyword>
  <keyword>Bronchial stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
    <mesh_term>Esophageal Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

